Use of Mevidalin and other D1 positive allosteric modulators for slowing progression of Parkinson's disease

Use of Mevidalin and other D1 positive allosteric modulators for slowing progression of Parkinson's disease

The present invention relates to methods of treatment and dosing regimens for slowing the progression of Parkinson's disease using Mevidaline, also described as 2-(2, 6-dichlorophenyl)-1-[(1S, 3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3, 4-dihydroisoquinolin-2 (1H)-yl] ethanone...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SVENSSON KARL ANDERS INGEMAR, BIGLAND KRISTIN M
Format: Patent
Sprache:chi ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to methods of treatment and dosing regimens for slowing the progression of Parkinson's disease using Mevidaline, also described as 2-(2, 6-dichlorophenyl)-1-[(1S, 3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3, 4-dihydroisoquinolin-2 (1H)-yl] ethanone, and/or pharmaceutical compositions thereof. 本发明涉及使用美维达林，也描述为2-(2,6-二氯苯基)-1-[(1S,3R)-3-(羟甲基)-5-(3-羟基-3-甲基丁基)-1-甲基-3,4-二氢异喹啉-2(1H)-基]乙酮和/或其药物组合物来减缓帕金森氏病进展的治疗方法和给药方案。